Overview

Study of Apatinib and MASCT in Patients With Advanced Solid Tumors

Status:
Unknown status
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
The study is aimed to evaluate the efficacy and safety of Apatinib and MASCT in patients with advanced solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The First People's Hospital of Lianyungang
Collaborators:
Hengrui Yuanzheng Bio-Technology Co., Ltd.
HengRui YuanZheng Bio-Technology Co.,Ltd.
Treatments:
Apatinib